Intravitreal Tissue Plasminogen Activator Injection for Treatment-Resistant Diabetic Macular Edema of the Vitrectomized Eye

Intravitreal Tissue Plasminogen Activator Injection for Treatment-Resistant Diabetic Macular Edema of the Vitrectomized Eye

Diabetic macular edema (DME) is the main cause of visual loss in patients with diabetic retinopathy. DME has been treated using intravitreal anti-vascular endothelial growth factor (VEGF) drugs, steroids, laser photocoagulation, vitreoretinal surgery, and their combinations. These modalities are gen...

Full description

Bibliographic Details
Main Authors: Ren Aoki, Makoto Hatano, Fumiaki Higashijima, Takuya Yoshimoto, Masanori Mikuni, Tadahiko Ogata, Yuka Kobayashi, Makiko Wakuta, Kazuhiro Kimura
Format: Article
Language:English
Published: Karger Publishers 2021-10-01
Series:Case Reports in Ophthalmology
Subjects:
tissue plasminogen activator
diabetic macular edema
vitrectomized eye
central retinal thickness
visual acuity
Online Access:https://www.karger.com/Article/FullText/518289

Internet

https://www.karger.com/Article/FullText/518289

Similar Items